ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
33 hedge funds and large institutions have $29.3M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 10 closing their positions.
6% more call options, than puts
Call options by funds: $19K | Put options by funds: $18K
11% less funds holding
Funds holding: 37 → 33 (-4)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
31% less capital invested
Capital invested by funds: $42.6M → $29.3M (-$13.3M)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$2.25M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.62M |
| 3 |
Barclays
London,
United Kingdom
|
+$480K |
| 4 |
WW
Waterfront Wealth
Overland Park,
Kansas
|
+$405K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$317K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$749K |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$445K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$445K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$308K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$213K |
ASLN Hedge Fund Activity: Q4 2021 in Review
33 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q4 2021, worth a combined $29.3M — down 31% from $42.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ASLN and 7 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $2.25M. The largest seller was Ikarian Capital, cutting an estimated $749K.
- 33 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q4 2021, down from 37 in Q3 2021.
- Funds reported $29.3M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q4 2021, down 31% quarter-over-quarter.
- 7 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q4 2021 and 10 closed out, a net change of -3 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q4 2021 was Silverarc Capital Management, an estimated $2.25M added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q4 2021 was Ikarian Capital, an estimated $749K sold.
Based on aggregated 13F filings for Q4 2021.